She will also serve as Associate Chief of the Division of Hematology/Oncology at Boston Children's Hospital
Kimberly Stegmaier, MD, was named Chair of Pediatric Oncology at Dana-Farber Cancer Institute and Associate Chief of the Division of Hematology/Oncology at Boston Children's Hospital, in an announcement made today. Her appointment is effective April 1, 2025.
A Dana-Farber, Boston Children's Hospital, and Harvard Medical School faculty member since 2002 and independent investigator since 2006, Stegmaier is currently the Vice Chair for Pediatric Oncology Research at Dana-Farber, Co-Director of the Pediatric Hematologic Malignancy Program at Dana-Farber and Boston Children's Hospital, Co-Leader for the Dana-Farber/Harvard Cancer Center Leukemia Program, and a Professor of Pediatrics at Harvard Medical School. She holds the Ted Williams Chair at Dana-Farber and is an Institute Member in the Cancer Program at the Broad Institute of Harvard and MIT.
"I am proud to know and to have worked alongside Kim for many years. She is deeply devoted to our young patients and their families and to the quest for new therapies. I am excited for her to lead our Department of Pediatric Oncology and to build on its strong foundation for years to come," said Benjamin L. Ebert, MD, PhD, president and CEO, Dana-Farber Cancer Institute.
As Chair of Pediatric Oncology, Stegmaier will be responsible for the full scope of clinical, research and educational activities of the department. She will work closely with David Williams, MD, Chief of the Division of Hematology/Oncology at Boston Children's Hospital to lead the Dana-Farber/Boston Children's Cancer and Blood Disorders Center.
A highly skilled physician-scientist, Stegmaier is dedicated to the goal of precision pediatric oncology medicine, pioneering the development and application of innovative genomic approaches to identify new therapies for childhood cancer. She has focused her efforts on acute leukemias and pediatric solid tumors of childhood, particularly those driven by fusion oncoproteins. Her lab has discovered novel technologies, concepts, and targets with translational impact.
Stegmaier is a principal investigator and renowned scientist who has been recognized by a range of national and international organizations, including the National Cancer Institute, where she twice earned the NCI Outstanding Investigator Award and the Society for Pediatric Research, where she received the E. Mead Johnson Award. A dedicated mentor, she was also the recipient of the A. Clifford Barger Excellence in Mentoring Award from Harvard Medical School. Stegmaier is an elected member of the Association of American Physicians (AAP) and the American Society for Clinical Investigation (ASCI), as well as a Board Member of the American Association for Cancer Research (AACR).
She earned a BS from Duke University and an MD from Harvard Medical School, and completed her residency at Boston Children's and a pediatric hematology-oncology fellowship at Dana-Farber/Boston Children's.
Stegmaier's appointment to this new role follows a nationwide search to succeed Scott Armstrong, MD, PhD, who was recently appointed to Senior Vice President for Drug Discovery and Chief Research Strategy Officer at Dana-Farber.
